Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

FATEBullishCorporate Developmentsnews

High materiality8/10

Fate Therapeutics Secures $15M CIRM Grant to Advance FT819 Lupus Nephritis Trial

Sep 25, 2026, 7:49 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Non-dilutive funding lowers financial risk and may lift sentiment around FT819's path to registrational trials, potentially supporting a re-rating in expectation of later-stage data.

AI summary

What happened, with direct paths to the underlying reporting

Fate Therapeutics received a $15 million CLIN2 grant from CIRM to support RECLAIM-LN, a Phase 2, potentially registrational FT819 trial for lupus nephritis. The program aims to deliver off-the-shelf CAR T therapy in outpatient settings, expanding access for refractory SLE with LN, with about 53 patients and RMAT/CDRP regulatory pathways backing development.

CIRM awards Fate $15M CLIN2 grant for FT819 lupus nephritis trial.
Trial RECLAIM-LN targets refractory SLE with LN; ~53 patients enrolled.
Primary endpoint: complete renal response at Week 26; RMAT/CDRP program support.
FT819 is off-the-shelf CD19 CAR T; aims outpatient community access.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.